Third Harmonic Bio, Inc. (THRD)
NASDAQ$3.43-0.02 (-0.58%)
Market Cap
$155.45M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
879 of 924
Rank in Industry
500 of 527
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
THRD Insider Trading Activity
THRD Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 0 | 0 |
Sells | $15,486,233 | 13 | 100 |
Related Transactions
| Conner Edward R. | Chief Medical Officer | 0 | $0 | 3 | $143,700 | $-143,700 |
| Person Julie | CHIEF ADMINISTRATIVE OFFICER | 0 | $0 | 4 | $278,366 | $-278,366 |
| Dittman Jennifer | Chief Development Oper Officer | 0 | $0 | 3 | $352,654 | $-352,654 |
| Holles Natalie C. | CEO | 0 | $0 | 2 | $411,514 | $-411,514 |
| BVF PARTNERS L P/IL | See Explanation of Responses | 0 | $0 | 1 | $14.3M | $-14.3M |
About Third Harmonic Bio, Inc.
Third Harmonic Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development of the medicine for the treatment of allergic and inflammatory diseases. It develops THB001, an oral small-molecule KIT inhibitor for the treatment of chronic urticaria, a dermatologic disease driven by mast cell activation that results in red, itchy, painful welts, or hives, as well as for airway and gastrointestinal tract indications. The company was formerly known as Project IGE, Inc. and changed its name to Third Harmonic Bio, Inc. in June 2019. …
Insider Activity of Third Harmonic Bio, Inc.
Over the last 12 months, insiders at Third Harmonic Bio, Inc. have bought $0 and sold $15.49M worth of Third Harmonic Bio, Inc. stock.
On average, over the past 5 years, insiders at Third Harmonic Bio, Inc. have bought $16.18M and sold $7.83M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 214,063 shares for transaction amount of $879,499 was made by BVF PARTNERS L P/IL (director) on 2022‑12‑20.
List of Insider Buy and Sell Transactions, Third Harmonic Bio, Inc.
| 2024-11-08 | Sale | Conner Edward R. | Chief Medical Officer | 2,117 0.0055% | $15.00 | $31,755 | -56.53% | |
| 2024-10-29 | Sale | BVF PARTNERS L P/IL | See Explanation of Responses | 1M 2.4872% | $14.30 | $14.3M | -29.22% | |
| 2024-10-28 | Sale | Conner Edward R. | Chief Medical Officer | 2,673 0.007% | $15.00 | $40,095 | -28.62% | |
| 2024-09-19 | Sale | Person Julie | CHIEF ADMINISTRATIVE OFFICER | 9,497 0.0236% | $14.29 | $135,685 | -24.17% | |
| 2024-09-19 | Sale | Conner Edward R. | Chief Medical Officer | 4,790 0.0125% | $15.00 | $71,850 | -24.17% | |
| 2024-09-18 | Sale | Person Julie | CHIEF ADMINISTRATIVE OFFICER | 503 0.0012% | $14.00 | $7,042 | -16.96% | |
| 2024-06-26 | Sale | Person Julie | CHIEF ADMINISTRATIVE OFFICER | 10,000 0.0217% | $12.46 | $124,569 | -4.66% | |
| 2024-06-07 | Sale | Dittman Jennifer | Chief Development Oper Officer | 494 0.0012% | $14.17 | $7,000 | -15.41% | |
| 2024-05-20 | Sale | Dittman Jennifer | Chief Development Oper Officer | 1,042 0.0025% | $14.00 | $14,588 | -15.69% | |
| 2024-05-16 | Sale | Dittman Jennifer | Chief Development Oper Officer | 23,578 0.0576% | $14.04 | $331,066 | -14.62% | |
| 2024-05-09 | Sale | Holles Natalie C. | CEO | 20,222 0.0428% | $12.18 | $246,300 | -1.18% | |
| 2024-04-11 | Sale | Holles Natalie C. | CEO | 13,558 0.0287% | $12.19 | $165,214 | +0.33% | |
| 2024-04-04 | Sale | Person Julie | CHIEF ADMINISTRATIVE OFFICER | 1,107 0.0019% | $10.00 | $11,070 | +18.81% | |
| 2023-12-05 | Sale | Person Julie | Chief Administrative Officer | 12,863 0.023% | $10.30 | $132,484 | +26.25% | |
| 2023-12-05 | Sale | Conner Edward R. | Chief Medical Officer | 4,790 0.0084% | $10.03 | $48,062 | +26.25% | |
| 2022-12-20 | BVF PARTNERS L P/IL | director | 214,063 0.153% | $4.11 | $879,499 | +28.50% | ||
| 2022-09-19 | Atlas Venture Fund XI, L.P. | 10 percent owner | 300,000 0.887% | $17.00 | $5.1M | -70.12% | ||
| 2022-09-19 | ORBIMED ADVISORS LLC | 300,000 0.887% | $17.00 | $5.1M | -70.12% | |||
| 2022-09-19 | Bonita David P | 300,000 0.887% | $17.00 | $5.1M | -70.12% |
Total: 19
*Gray background shows transactions not older than one year
Insider Historical Profitability
28.5%
| BVF PARTNERS L P/IL | See Explanation of Responses | 176692 0.3921% | $609,587.40 | 1 | 1 | +28.5% |
| Atlas Venture Fund XI, L.P. | 10 percent owner | 10313763 22.8898% | $35.58M | 1 | 0 | |
| ORBIMED ADVISORS LLC | 5779071 12.8257% | $19.94M | 1 | 0 | ||
| Bonita David P | 5779071 12.8257% | $19.94M | 1 | 0 |
*Gray background shows insiders who have made transactions during last year
Historical Insider Profitability vs. Competitors
$2,924,567 | 72 | -4.87% | $154.84M | |
$35,190,048 | 32 | 37.32% | $154.45M | |
$79,019,806 | 27 | 7.24% | $166.54M | |
$6,915,275 | 21 | -32.61% | $147.81M | |
$2,484,989 | 17 | -17.86% | $158.42M |
THRD Institutional Investors: Active Positions
| Increased Positions | 62 | +80.52% | 8M | +18.9% |
| Decreased Positions | 31 | -40.26% | 5M | -12.36% |
| New Positions | 25 | New | 4M | New |
| Sold Out Positions | 13 | Sold Out | 784,620 | Sold Out |
| Total Postitions | 108 | +40.26% | 47M | +6.54% |
THRD Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Atlas Venture Life Science Advisors, Llc | $35,888.00 | 23.12% | 10.4M | -505,573 | -4.63% | 2024-12-31 |
| Orbimed Advisors Llc | $19,938.00 | 12.84% | 5.78M | 0 | 0% | 2024-12-31 |
| General Atlantic, L.P. | $11,635.00 | 7.49% | 3.37M | +413,561 | +13.98% | 2024-12-31 |
| Ecor1 Capital, Llc | $10,979.00 | 7.07% | 3.18M | 0 | 0% | 2024-12-31 |
| T. Rowe Price Investment Management, Inc. | $10,107.00 | 6.51% | 2.93M | +99,250 | +3.51% | 2024-12-31 |
| Fmr Llc | $8,751.00 | 5.64% | 2.54M | +2M | +723.58% | 2024-12-31 |
| Tcg Crossover Management, Llc | $8,644.00 | 5.57% | 2.51M | +90,424 | +3.74% | 2024-12-31 |
| Bvf Inc/Il | $8,187.00 | 5.27% | 2.37M | -2M | -45.65% | 2024-12-31 |
| Boxer Capital, Llc | $6,900.00 | 4.44% | 2M | 0 | 0% | 2024-09-30 |
| Boxer Capital Management, Llc | $6,900.00 | 4.44% | 2M | +2M | New | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.